asterias.jpg
Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
January 24, 2019 07:00 ET | Asterias Biotherapeutics
FREMONT, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
asterias.jpg
Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small Cell Lung Cancer
November 27, 2018 07:00 ET | Asterias Biotherapeutics
FREMONT, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and...
asterias.jpg
Asterias Biotherapeutics Reports Third Quarter Results
November 09, 2018 16:10 ET | Asterias Biotherapeutics
Clinical Programs Continue to ProgressRecent Transactions with affiliate of Novo Nordisk Increased Cash-on-Hand and Reduced Annual Operating ExpensesRecently Announced Definitive Merger Agreement with...
asterias.jpg
Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018
November 02, 2018 07:00 ET | Asterias Biotherapeutics
FREMONT, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
asterias.jpg
Asterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury Study
October 31, 2018 09:45 ET | Asterias Biotherapeutics
Meeting with Food and Drug Administration Remains on Track for End of 2018 FREMONT, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology...
asterias.jpg
Asterias Biotherapeutics Announces Facilities and IP License Option Agreements
October 01, 2018 07:00 ET | Asterias Biotherapeutics
FREMONT, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
asterias.jpg
FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program
September 20, 2018 07:00 ET | Asterias Biotherapeutics
FREMONT, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
asterias.jpg
Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
September 12, 2018 07:00 ET | Asterias Biotherapeutics
FREMONT, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
asterias.jpg
Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
September 04, 2018 07:00 ET | Asterias Biotherapeutics
FREMONT, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and...
asterias.jpg
Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference
August 29, 2018 07:00 ET | Asterias Biotherapeutics
FREMONT, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...